Blog
RSS FeedPosted by Michael Wonder on 11 Oct 2021
Belgium may remove step between paying doctors and reimbursement
8 October 2021 - Doctors and dentists could soon choose to only charge patients for co-payments – the non-refundable part ...
Posted by Michael Wonder on 24 Sep 2021
Pear Therapeutics announces additional coverage decisions and formulary adoption of its prescription digital therapeutics
23 September 2021 - More than 30 organizations now provide access to Pear’s prescription digital therapeutics by either listing on formulary, ...
Posted by Michael Wonder on 18 Aug 2021
Talks to recover reimbursement for dementia treatment aid almost complete
18 August 2021 - The negotiations on retrieving the reimbursement of pharmaceutical pricing for choline alfoscerate drugs to help treat ...
Posted by Michael Wonder on 17 Aug 2021
Oncopeptides' Pepaxto receives a permanent J code, clarifying reimbursement processes in hospital outpatient and physician office settings of care
16 August 2021 - Oncopeptides today announced that the Centers for Medicare and Medicaid Services has established a specific billing Level ...
Posted by Michael Wonder on 22 Apr 2021
Delcath Systems announces revised NICE guidance for Chemosat in the United Kingdom
21 April 2021 - Recommends special arrangement designation which increases reimbursement options. ...
Posted by Michael Wonder on 18 Jan 2021
HHS regulations with enduring impact on pricing and reimbursement of medical services and technologies
17 January 2021 - The Trump Administration’s grandiose healthcare plans didn’t come to fruition, like the promised repeal and replace of ...
Posted by Michael Wonder on 15 Dec 2020
COVID-19 vaccine codes: updated effective date for Pfizer-BioNTech
14 December 2020 - During the COVID-19 public health emergency, Medicare will cover and pay for the administration of the vaccine ...
Posted by Michael Wonder on 13 Dec 2020
Though promising, gene therapies face durability and reimbursement headwinds
11 December 2020 - The promise of gene therapy is to cure diseases associated with faulty or missing genes. There’s enormous ...
Posted by Michael Wonder on 05 Oct 2020
Radiopharmaceutical Lutathera now reimbursed in Quebec for cancer patients with advanced gastro-enteropancreatic neuroendocrine tumours
1 October 2020 - Lutathera is the first and only therapeutic radiopharmaceutical indicated in the treatment of GEP-NETs in Canada. ...
Posted by Michael Wonder on 21 Sep 2020
Pear Therapeutics and PreferredOne announce broad based patient access and reimbursement for reSET & reSET-O for people with substance use disorder and opioid use disorder
21 September 2020 - PreferredOne teams with Pear to provide its members with covered access to two prescription digital therapeutics for ...
Posted by Michael Wonder on 03 Sep 2020
CMS grants additional reimbursement for the Eluvia drug eluting vascular stent system
3 September 2020 - Boston Scientific announced that the U.S. Centers for Medicare and Medicaid Services granted a new technology add-on ...
Posted by Michael Wonder on 28 Jun 2020
The reimbursement for medicines is expected to decrease by SEK 185 million in 2020
26 June 2020 - Pharmaceutical companies will pay SEK 2.9 billion in reimbursement for medicines covered by side agreements between ...
Posted by Michael Wonder on 14 May 2020
Camurus' Buvidal reimbursed in Sweden for the treatment of opioid dependence
14 May 2020 - Buvidal (buprenorphine) prolonged release injection receives reimbursement in Sweden from the 15 May 2020 after approval by ...
Posted by Michael Wonder on 24 Feb 2020
Digital therapeutics leaders focus on reimbursement
23 February 2020 - This past week the Digital Therapeutics West conference was held in Silicon Valley. CEOs, venture capitalists, and ...
Posted by Michael Wonder on 25 Oct 2018
FDA's Gottlieb 'extremely worried' on CAR-T reimbursement
24 October 2018 - FDA Commissioner Scott Gottlieb stressed the need for reform on the reimbursement side of medicine, calling it ...